You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Infectious Diseases
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Login
Username:

Password:


Related Headlines

Roivant to announce Q3 2026 financial results

Blacksmith Medicines granted European patent for LpxC-targeting antibacterial compounds

Riyadh's 10th SPNS Conference Focuses on AI and Technology as Catalysts for Better Paediatric Neurology Care

ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines

AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding

PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt

Oxford Nanopore and bioMérieux introduce AmPORE-TB for rapid tuberculosis resistance characterisation

4basebio synthetic DNA used in Phase I/II mRNA therapy trial

Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis

Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio

Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities

60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study

INOVIO announces inducement grant to new employee

Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays

Appili Therapeutics and Vitalex Biosciences secure NIAID contract for fungal vaccine development for up to USD40m

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026